Uncategorized
Benefit-risk analysis supports as-needed anti-VEGF therapy vs. laser in treatment of DME
VIENNA — Benefit-risk analysis of phase 3 clinical trial data supports the favorable profile of ranibizumab 0.5 mg as-needed dosing compared with laser therapy for treatment of diabetic macular edema, according to a presentation here. Comparative benefit-risk assessment was conducted using the Benefit Risk Action Team Software Tool (BRAT), which encompasses a series of steps for selection, summarization, organization and interpretation of data.